What Signia Therapeutics does

Signia Therapeutics is a privately held French biotechnology startup founded in 2017 and headquartered in Lyon. The company is building a technology platform focused on treatments for respiratory infections, with its lead asset being a Diltiazem-based therapeutic approach to reduce viral load in hospitalized COVID-19 patients. This program was in a Phase IIb clinical trial as of October 2021, with the trial explicitly framed as a validation exercise for Signia's broader respiratory infections platform rather than a single-indication effort.

The company is pre-revenue and pre-commercialization. Its economics are entirely dependent on equity and grant capital: it has raised approximately $3.5 million cumulatively across an EISMEA grant in 2018 (~$83K), a €1.3 million strategic investment from Néovacs in October 2021, and a ~$1.92 million Bpifrance round in January 2022. Philippe Personne serves as CEO and Manuel Rosa Calatrava as scientific co-founder. With 1–10 employees, no manufacturing, no marketing or distribution infrastructure, and no disclosed licensing revenue, the business model at this stage is a clinical-development optionality bet on Phase IIb read-out success and downstream out-licensing, partnership, or further equity financing.

Customer segmentation is therefore not commercial but clinical: the primary 'use case' segment is hospitalized COVID-19 patients enrolled in the Phase IIb trial in Lyon. There are no disclosed paying customers, no channel partnerships, and no pricing structure. The company's website (signiatherapeutics.com) currently displays content unrelated to its biotech activity, suggesting limited investor-facing or commercial maturity. Geographic footprint is restricted to France, with no disclosed plans for multi-region trials at the data presented.

Name

Signia Therapeutics

Website

https://signiatherapeutics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Signia Therapeutics is a French clinical-stage biotechnology startup developing a Diltiazem-based therapy for hospitalized COVID-19 patients in Phase IIb trials, while validating a broader respiratory infections platform. The company is pre-revenue with 1–10 employees.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Respiratory therapeutics
• Clinical stage biotechnology
• Drug repurposing platform
• Antiviral treatments
• Infectious disease research

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Core offering

Signia Therapeutics is a clinical-stage biotechnology company developing a proprietary technology platform for the treatment of respiratory infections. Its lead program is a Diltiazem-based COVID-19 therapeutic currently in a Phase IIb clinical trial evaluating the drug's effect on viral load in hospitalized patients.

Product overview

Signia Therapeutics is a biotechnology company based in Lyon, France, focused on developing treatments for respiratory infections. The company operates a technology platform that was being validated through a Phase IIb clinical trial for a COVID-19 treatment using Diltiazem as of October 2021.

Differentiator

Problem solved

Functional benefit

Products and services

• Diltiazem-based COVID-19 Treatment (Phase IIb Clinical Program) Clinical-stage therapeutic candidate using Diltiazem (a repurposed calcium channel blocker) intended to reduce viral load in hospitalized COVID-19 patients; currently in Phase IIb clinical evaluation.

Quantifiable outcome

• Phase IIb clinical trial evaluating drug effect on viral load in hospitalized patients

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights2 records

Emerging players

• Abivax: French clinical-stage biotechnology company developing small-molecule therapies in immunology and viral diseases; directly comparable to Signia by geography (France), size, and clinical-stage small-molecule approach.
• AB Science: Paris-based clinical-stage biopharma developing small-molecule tyrosine kinase inhibitors; comparable to Signia as a small French clinical-stage biotech with a single-platform technology approach.
• DBV Technologies: French clinical-stage biotech (Montrouge) developing allergy and immunology products; comparable to Signia as a small French clinical-stage life sciences company navigating capital-constrained development.
• Valneva: European specialty vaccine and antibody company with COVID-19 and other respiratory infection programs; comparable to Signia in European footprint and respiratory infectious disease focus.
• Innate Pharma: Marseille-based clinical-stage biotech developing antibody-based immunotherapies; comparable to Signia as a small French clinical-stage life sciences company.
• RedHill Biopharma: Specialty pharma developing small-molecule therapeutics for gastrointestinal and infectious diseases, including COVID-19; comparable as a small-cap commercial/clinical-stage company using small molecules in viral infections.

Broad incumbents

• BioNTech: European (German) biopharma with leading COVID-19 vaccine franchise and ongoing infectious disease pipeline; relevant broad incumbent shaping the COVID-19 and respiratory infection landscape Signia operates in.
• Novavax: Larger clinical/commercial-stage vaccine developer with a COVID-19 vaccine and broader respiratory pipeline; comparable to Signia in the respiratory infection therapeutic area, though much larger and more diversified.
• Pfizer: Global pharmaceutical company and developer of Paxlovid (nirmatrelvir/ritonavir) for COVID-19; relevant broad incumbent that defines the competitive standard of care in the indication Signia is targeting.

Direct peers

• Atea Pharmaceuticals: Clinical-stage biopharma developing oral small-molecule antivirals for RNA viruses including COVID-19, RSV, and influenza; directly comparable to Signia in stage, modality (small molecule), and therapeutic area (respiratory viral infections).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Signia Therapeutics